

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application.

Listing of Claims:

Claims 1 – 5. Cancelled.

Claims 6 – 8. Cancelled.

9 (Currently Amended). A therapeutic vaccine according to claim 28, wherein at least one of the one or more polypeptides ~~or fragments thereof~~, is fused to at least one fusion partner which is an antigen expressed by bacteria within the mycobacteria family.

10 (Previously Presented). A therapeutic vaccine according to claim 9 where the fusion partner is selected from the group consisting of ESAT-6, ESAT-6-Ag85B, TB10.4, CFP10, RD1-ORF5, RD1-ORF2, Rv1036, MPB64, MPT64, Ag85A, Ag85B (MPT59), MPB59, Ag85C, 19kDa lipoprotein, MPT32.

Claim 11. Cancelled.

12 (Previously Presented). A vaccine according to claim 28, further comprising antigen components with prophylactic activity.

13 (Previously Presented). A vaccine according to claim 12 where the antigen components with prophylactic activity are selected from the group consisting of ESAT-6, ESAT-6-Ag85B, TB10.4, CFP10, RD1-ORF5, RD1-ORF2, Rv1036, MPB64, MPT64, Ag85A, Ag85B (MPT59), MPB59, Ag85C, 19kDa lipoprotein or MPT32.

Claims 14 and 15. Cancelled.

Claim 16 (Currently Amended). A therapeutic vaccine according to claim 28, where the polypeptides ~~or fragments~~ are recombinant or synthetic and are delivered in a delivery system such as an adjuvant.

Claim 17 (Currently Amended). A therapeutic vaccine according to claim 28, in which the polypeptide ~~or fragment~~ is lipidated so as to allow a self-adjuvanting effect of the polypeptide.

Claims 18 – 23. Cancelled.

24 (Previously Presented). The therapeutic vaccine according to claim 28, wherein the polymeric carrier and the one or more polypeptide(s) are bound by non-covalent interactions.

25 (Previously Presented). The therapeutic vaccine according to claim 24, wherein the polymeric carrier is a polystyrene.

26 (Currently Amended). The therapeutic vaccine according to claim 28, wherein the polymeric carrier and the one or more polypeptide(s) ~~or fragments thereof~~ are bound by covalent interactions.

27 (Previously Presented). The therapeutic vaccine according to claim 26, wherein the polymeric carrier is selected from the group consisting of a polysaccharide or a polypeptide.

28 (Previously Presented). A therapeutic vaccine against tuberculosis comprising one or more mycobacteria polypeptides and a pharmaceutically acceptable polymeric carrier bound to the one or more polypeptides or a pharmaceutically acceptable adjuvant, which polypeptides are upregulated or expressed during the latent

stage of the mycobacteria infection which is characterized by low-oxygen tension in the microenvironment of the mycobacteria.

29 (Currently Amended) ~~The therapeutic vaccine according to claim 28A~~
therapeutic vaccine against tuberculosis comprising one or more mycobacteria
polypeptides and a pharmaceutically acceptable polymeric carrier bound to the one or
more polypeptides or a pharmaceutically acceptable adjuvant, which polypeptides are
upregulated or expressed during the latent stage of the mycobacteria infection which is
characterized by low-oxygen tension in the microenvironment of the mycobacteria,
wherein the one or more polypeptides has an amino acid sequence selected from SEQ ID
NO 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25,
26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44 and 45.

30 (New). The therapeutic vaccine according to claim 29, wherein the one or
more polypeptides has an amino acid sequence of SEQ ID NO:24.

31 (New). The therapeutic vaccine according to claim 29, wherein at least one
of the one or more polypeptides is fused to at least one fusion partner which is an antigen
expressed by bacteria within the mycobacteria family.

32 (New). The therapeutic vaccine according to claim 31 where the fusion
partner is selected from the group consisting of ESAT-6, ESAT-6-Ag85B, TB10.4,
CFP10, RD1-ORF5, RD1-ORF2, Rv1036, MPB64, MPT64, Ag85A, Ag85B (MPT59),
MPB59, Ag85C, 19kDa lipoprotein, MPT32.

33 (New). The therapeutic vaccine according to claim 29 further comprising the
antigen components with prophylactic activity are selected from the group consisting of
ESAT-6, ESAT-6-Ag85B, TB10.4, CFP10, RD1-ORF5, RD1-ORF2, Rv1036, MPB64,
MPT64, Ag85A, Ag85B (MPT59), MPB59, Ag85C, 19kDa lipoprotein or MPT32.

34 (New). The therapeutic vaccine according to claim 29, where the polypeptides are recombinant or synthetic and are delivered in a delivery system comprising an adjuvant.

35 (New). The therapeutic vaccine according to claim 29, in which the polypeptide is lipidated thereby providing a self-adjuvanting effect of the polypeptide.

36 (New) The therapeutic vaccine according to claim 29, which comprises a polymeric carrier bound by covalent or non-covalent interactions to at least one of the one or more polypeptides.

37 (New). The therapeutic vaccine according to claim 36, wherein the polymeric carrier is a polystyrene.

38 (New). A therapeutic vaccine against tuberculosis comprising one or more mycobacteria peptides and a pharmaceutically acceptable polymeric carrier bound to the one or more peptides or a pharmaceutically acceptable adjuvant, which polypeptides are upregulated or expressed during the latent stage of the mycobacteria infection which is characterized by low-oxygen tension in the microenvironment of the mycobacteria, wherein the one or more peptides has an amino acid sequence selected from a peptide comprising amino acids 11 to 30 of SEQ ID NO: 24 and a peptide comprising amino acids 81 to 100 of SEQ ID NO: 24.

39 (New). The therapeutic vaccine according to claim 38, wherein at least one of the one or more peptides is fused to at least one fusion partner which is an antigen expressed by bacteria within the mycobacteria family.

40 (New). The therapeutic vaccine according to claim 39 where the fusion partner is selected from the group consisting of ESAT-6, ESAT-6-Ag85B, TB10.4, CFP10, RD1-ORF5, RD1-ORF2, Rv1036, MPB64, MPT64, Ag85A, Ag85B (MPT59), MPB59, Ag85C, 19kDa lipoprotein, MPT32.